Deutsche Bank analyst Andrew Peters downgraded shares of Exelixis, Inc (NASDAQ: ) on Thursday, while raising his price target from $26 to $29. The company had been Deutsche Bank’s top pick since initiating coverage on the biotech sector last year. The downgrade wasn't a result of downsides ahead though, Peters sees Exelixis “as an undisputed success story in biotech.” Instead, the company is simply lack new catalysts.Read more